FDA Generic Labeling Rule: PhRMA, GPhA Offer Degrees Of Dislike

GPhA argues it would be impossible for ANDA applicants to unilaterally change their labels; Pfizer suggests FDA only allow one request for a proposed labeling change on a given safety issue at a time.